Deficiency in CYP7A1 in humans leads to significant metabolic aberrations, including impaired conversion of cholesterol to BAs, accumulation of hepatic cholesterol, reduction of LDL receptor expression, exacerbated hypercholesterolemia, and diminished statin response. Here, CYP7A1 is linked to familial hypercholesterolemia.